Letrozole Combined With Anlotinib Hydrochloride in the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Summary

The study is a prospective, single-arm, open label, exploratory phase 2 clinical trial, which aims to study the therapeutic effect of letrozole combined with anlotinib hydrochloride in platinum-resistant recurrent ovarian cancer.

Timeline

Start

2020-09-01

Primary completion

2022-08-31

Completion

2023-09-30

Publications

• Wang Y, Li J, Yang Y, Lu X, Xu H, Zhao S, Guan W, Wang X. Letrozole plus anlotinib as a chemotherapy-free regimen for ER-positive platinum-resistant recurrent epithelial ovarian cancer patients following second-line platinum-based chemotherapy failure: A prospective, single-arm, open-label, phase II study. Gynecol Oncol. 2025 Dec;203:67-74. doi: 10.1016/j.ygyno.2025.10.023. Epub 2025 Oct 29.

Drugs

Indications